With R&D laboratories and manufacturing operations in Kentucky, Intranasal Therapeutics Inc - in 2009 having changed the firm's name to Ikano Therapeutics - is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system for which there is proven, unsatisfied consumer need. At the time of their SBIR involvement, the firm had four products in the pipeline, with several others in formulation or preclinical development.
